TY  - GEN
AU  - De Diego-Adelino, Javier
AU  - Crespo, Jose Manuel
AU  - Mora, Fernando
AU  - Neyra, Adrian
AU  - Iborra, Pedro
AU  - Gutierrez-Rojas, Luis
AU  - Salonia, Selman F.
PY  - 2021
DO  - 10.1080/14740338.2022.2019705
SN  - 1474-0338
UR  - https://hdl.handle.net/10668/26044
T2  - Expert opinion on drug safety
AB  - Introduction Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options...
LA  - en
PB  - Taylor & francis ltd
KW  - Antidepressant
KW  - cognition
KW  - efficacy
KW  - interactions
KW  - major depressive disorder
KW  - neurotransmission
KW  - pharmacology
KW  - safety
KW  - vortioxetine
KW  - Serotonin reuptake inhibitors
KW  - Multimodal antidepressant vortioxetine
KW  - Randomized controlled-trials
KW  - Emergent sexual dysfunction
KW  - Placebo-controlled trials
KW  - Substance use disorders
KW  - Inadequate response
KW  - Double-blind
KW  - 5-ht3 receptors
KW  - Open-label
TI  - Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review
TY  - review
VL  - 21
ER  -